Eli Lilly sues six companies over illegal sales of experimental obesity drug retatrutide
Lilly filed six lawsuits targeting a black market for its unapproved GLP-1 triple agonist retatrutide, alleging illegal sales of knockoffs.
Reuters · +14 outlets
UK becomes first European country to approve Eli Lilly's oral obesity pill Foundayo (orforglipron)
The MHRA granted marketing authorization for Lilly's once-daily oral GLP-1 agonist, marking the first European approval of the drug.
pharmaphorum · +14 outlets
Compass Pathways achieves primary endpoint in Phase 3 treatment-resistant depression trial with COMP360
Shares of Compass rose as its psilocybin therapy met its primary endpoint, with analysts projecting potential FDA approval by H1 2027.
Stocktwits · +14 outlets
Epicrispr lands $90M Series A to advance epigenetic editing drug for rare muscle disease
The startup will use the funds to develop a first-in-class epigenetic editing therapy for facioscapulohumeral muscular dystrophy.
BioPharma Dive
Eli Lilly's triple agonist retatrutide just became its most powerful obesity drug yet, new data show
New analyses indicate Lilly's triple GIP/GLP-1/glucagon agonist retatrutide continues to show best-in-class weight loss potential.
Drug Discovery News · +14 outlets
Vaderis nets $152M Series B to test AKT-targeting drug
The Swiss biotech raised one of the largest private rounds of the year to advance its AKT inhibitor program into the clinic.
BioPharma Dive · +1 outlets
GRAIL stock faces major moves ahead of FDA decision on Galleri multi-cancer test
Analysts are looking beyond the NHS-Galleri headline as a US FDA decision for GRAIL's blood-based cancer screening test approaches.
Pluang · +3 outlets
Eli Lilly opens $50-a-month Medicare access to obesity drugs
Lilly is offering certain obesity drugs to Medicare beneficiaries at $50 per month through a new program.
simplywall.st · +14 outlets
NeOnc Technologies reports positive Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma
Five of 24 glioma patients remain on the at-home nasal therapy, showing potential for a non-invasive brain cancer treatment.
Quiver Quantitative · +10 outlets
Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas
Major biopharma companies reported strong second-quarter sales growth, driven by key product performance.
Fierce Pharma
Sun Pharma faces major legal setback in semaglutide launch amid Novo Nordisk lawsuit
A court ruling blocked Sun Pharma from launching its semaglutide copy, dealing a blow to its entry into the GLP-1 obesity market.
streamlinefeed.co.ke · +1 outlets
Merck KGaA partner Remepy raises $36M Series A for 'hybrid drug' platform
The startup is developing a platform that combines small molecules with biologics for enhanced drug properties.
AllSci · +2 outlets
Improvement in rare disease biotech investing after FDA's PRV program renewal
Renewal of the FDA Priority Review Voucher program has spurred renewed investment in rare disease biotech.
Pharmaceutical Executive · +10 outlets
InduPro assembles $77M; Vaderis nets $152M series B in Fierce Biotech Fundraising Tracker
Two biotechs raised significant venture rounds, with InduPro collecting $77M for its proximity-based protein targeting platform.
fiercebiotech.com
JW Pharma's epaminurad 6 mg outperforms febuxostat 40 mg in Phase 3 gout trial
JW Pharmaceutical's novel urate-lowering agent showed superior efficacy compared to the standard of care in a Phase 3 study.
koreabiomed.com · +2 outlets
Achieve's cytisinicline study finds 24.4% abstinence vs. 15.8% placebo for smoking cessation
The Phase 3 trial of cytisinicline met its primary endpoint, showing a statistically significant improvement in smoking cessation rates.
Stock Titan
Gan & Lee Pharmaceuticals hits daily limit up on GLP-1 deal with European partner worth up to €664M
Chinese biotech Gan & Lee surged after licensing out its GLP-1 drug candidate to a European partner in a deal potentially worth over half a billion euros.
finance.biggo.com
PRAX stock drops 12% after hours on trial setback; retail eyes FDA approval of other pipeline candidates
Shares of Praxis Precision Medicines fell after a clinical setback, though focus shifted to other pipeline programs.
Stocktwits · +1 outlets